Compositions and methods for treating alpha-1 antitrypsin deficiency
Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of α1-antitrypsin (AAT), such as seen in subjects having α1-antitrypsin deficiency (AATD), are provided.
1. A composition comprising a guide RNA comprising a guide sequence of SEQ ID NO: 42 or a guide sequence that is at least 90% identical to SEQ ID NO: 42 wherein the guide RNA is a single guide RNA (sgRNA) comprising 2′-O-methyl (2′-O-Me) modified nucleotides at the first three nucleotides at the 5′ end and/or 2′-O-Me modified nucleotides at the last three nucleotides at the 3′ end.
2. The composition of claim 1 , wherein the guide sequence is SEQ ID NO: 42.
3. The composition of claim 2 , wherein the guide RNA comprises a guide sequence of SEQ ID NO: 42 and further comprises SEQ ID NO: 141 at the 3′ end of SEQ ID NO: 42.
4. The composition of claim 2 , wherein the guide RNA comprises mC*mA*mA*CCUCACGGAGAUUCCGGGUUUUAGAmGmCmUmAmGmAmAmAmUmA mGmCAAGUUAAAAUAAGGCUAGUCCGUUAUCAmAmCmUmUmGmAmAmAmAmAm GmUmGmGmCmAmCmCmGmAmGmUmCmGmGmUmGmCmU*mU*mU*mU (SEQ ID NO: 138), wherein a * indicates a phosphorothioate (PS) linkage and a lower case “m” indicates that the nucleotide is 2′-O-Me modified.
5. The composition of claim 1 , wherein the sgRNA comprises a guide sequence that has the modifications of SEQ ID NO: 130 or wherein the sgRNA comprises SEQ ID NO: 130.
6. The composition of claim 5 , wherein each N in SEQ ID NO: 130 is any natural or non-natural nucleotide, wherein the N's form the guide sequence, and the guide sequence targets an RNA-guided DNA binding agent to the SERPINA1 gene.
7. The composition of claim 6 , wherein each N in SEQ ID NO: 130 is collectively replaced with a guide sequence of SEQ ID NO: 42.
8. The composition of claim 1 , wherein the guide RNA comprises at least one further modification comprising
a. a 2′-O-methyl (2′-O-Me) modified nucleotide;
b. a phosphorothioate (PS) bond between nucleotides;
c. a 2′-fluoro (2′-F) modified nucleotide;
d. a modification at one or more of the first five nucleotides at the 5′ end;
e. a modification at one or more of the last five nucleotides at the 3′ end;
f. PS bonds between the first four nucleotides;
g. PS bonds between the last four nucleotides; or
h. a combination of two or more of (a)-(g).
9. The composition of claim 8 , wherein the at least one modification comprises phosphorothioate (PS) bonds between the first four nucleotides and/or between the last four nucleotides.
10. The composition of claim 1 , wherein the guide RNA comprises a guide sequence that is at least 95% or 90% identical to SEQ ID NO: 42.
11. The composition of claim 10 , wherein the guide RNA further comprises SEQ ID NO: 141 at the 3′ end of the guide sequence.
12. The composition of claim 11 , comprising the modification pattern of SEQ ID NO: 130.
13. The composition of claim 1 , wherein the guide RNA is associated with a lipid nanoparticle (LNP).
14. The composition of claim 1 , wherein the guide RNA and an RNA-guided DNA binding agent or a nucleic acid encoding an RNA-guided DNA binding agent are associated with a lipid nanoparticle (LNP).
15. The composition of claim 14 , wherein the LNP comprises Lipid A (((9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate) and/or PEG2k-DMG.
16. The composition of claim 1 , wherein the composition further comprises an RNA-guided DNA binding agent or comprises an mRNA that encodes an RNA-guided DNA binding agent.
17. The composition of claim 16 , wherein the RNA-guided DNA binding agent is Cas9 from S. pyogenes.
18. The composition of claim 1 , wherein the composition is a pharmaceutical formulation and further comprises a pharmaceutically acceptable carrier.
19. The composition of claim 1 , wherein the sgRNA comprises a sequence selected from SEQ ID NOs: 130, 410-414, and 416-421, wherein each N in the sequence is collectively replaced with a guide sequence of SEQ ID NO: 42 or a guide sequence that is at least or 90% identical to SEQ ID NO: 42.
20. A viral vector comprising the composition of claim 1 .
21. A lipid nanoparticle comprising the composition of claim 1 .